Influenza and myocardial infarction

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 2, 2010, Pages 143-146

  Warren Gash, Charlotte ^a   Smeeth, Liam ^b   Hayward, Andrew ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; ANTICOAGULANT AGENT; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; INTERLEUKIN 6; OSELTAMIVIR; TUMOR NECROSIS FACTOR ALPHA; ZANAMIVIR; ANTIVIRUS AGENT; AUTACOID;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; EDITORIAL; ENVIRONMENTAL FACTOR; HUMAN; INFECTION RISK; INFLAMMATORY DISEASE; INFLUENZA; INFLUENZA VIRUS A H1N1; LIFESTYLE; NONHUMAN; PANDEMIC; RISK REDUCTION; SEASONAL INFLUENZA; VIRUS INFECTION; ANIMAL; BLOOD; HEART INFARCTION; MORTALITY; PHYSIOLOGY; RISK FACTOR;

ANIMALS; ANTIVIRAL AGENTS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION MEDIATORS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 77951913520     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.188     Document Type: Editorial

References (40)

1. Alber DG, Powell KL, Vallance P, Goodwin DA, Grahame-Clarke C. Herpes virus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation 102(7), 779-785 (2000).
2. Bjorkbacka H, Kunjathoor VV, Moore KJ et al. Reduced atherosclerosis in MyD88- null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 10(4), 416-421 (2004).
3. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340(2), 115-126 (1999).
4. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br. Med. J. 321(7255), 199-204 (2000).
5. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350(14), 1387-1397 (2004).
6. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 296(14), 1735-1741 (2006).
7. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J. Rheumatol. 30(6), 1196-1202 (2003).
8. Hingorani AD, Cross J, Kharbanda RK et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 102(9), 994-999 (2000).
9. Kharbanda RK, Walton B, Allen M et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 105(22), 2600-2604 (2002).
10. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 351(25), 2611-2618 (2004).
11. Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol. Infect. 110(1), 145-160 (1993).
12. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect. Dis. 9(10), 601-610 (2009).
13. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur. Heart J. 29(1), 96-103 (2008).
14. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 351(9114), 1467-1471 (1998).
15. Chi CY, Wang SM, Lin CC et al. Clinical features of children infected with different strains of influenza B in southern Taiwan. Pediatr. Infect. Dis. J. 27(7), 640-645 (2008).
16. Bishop JF, Murnane MP, Owen R. Australia's winter with the 2009 pandemic influenza A (H1N1) virus. N. Engl. J. Med. 361(27), 2591-2594 (2009).
17. Cretikos MA, Muscatello DJ, Patterson J. Progression and impact of the first winter wave of the 2009 pandemic H1N1 influenza in New South Wales, Australia. Euro. Surveill. 14(42), article 6 (2009).
18. Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro. Surveill. 14(33), pii 19309 (2009).
19. Szretter KJ, Gangappa S, Lu X et al. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J. Virol. 81(6), 2736-2744 (2007).
20. Keller TT, Van Der Sluijs KF, de Kruif MD et al. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ. Res. 99(11), 1261-1269 (2006).
21. Muramoto Y, Ozaki H, Takada A et al. Highly pathogenic H5N1 influenza virus causes coagulopathy in chickens. Microbiol. Immunol. 50(1), 73-81 (2006).
22. Garcia-Moll X. Influenza vaccination: a new indication of an old therapy? Rev. Esp. Cardiol. 56(10), 944-946 (2003).
23. Di Stefano R, Di Bello V, Barsotti MC et al. Inflammatory markers and cardiac function in acute coronary syndrome: Difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models. Biomed. Pharmacother. 63(10), 773-780 (2009).
24. Hamer M, Chida Y, Stamatakis E. Association of very highly elevated C-reactive protein concentration with cardiovascular events and all-cause mortality. Clin. Chem. 56(1), 132-135 (2009).
25. Shah T, Casas JP, Cooper JA et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int. J. Epidemiol. 38(1), 217-231 (2009).
26. Helfand M, Buckley DI, Freeman M et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann. Intern. Med. 151(7), 496-507 (2009).
27. Ciszewski A, Bilinska ZT, Brydak LB et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur. Heart J. 29(11), 1350-1358 (2008).
28. Gurfinkel EP, Leon de la FR, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur. Heart J. 25(1), 25-31 (2004).
29. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
30. Hayward A. Influenza A (H1N1) pandemic: true or false alarm. J. Epidemiol. Community Health 63(10), 775-776 (2009).
31. Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. Pharmacoepidemiol. Drug Saf. 13(4), 227-237 (2004).
32. Ward Casscells S, Granger E, Kress AM, Linton A, Madjid M, Cottrell L. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases. Circ. Cardiovasc. Qual. Outcomes 2, 108-115 (2009).
33. Paciaroni M, Bogousslavsky J. Statins and stroke prevention. Expert Rev. Cardiovasc. Ther. 7(10), 1231-1243 (2009).
34. Tuttolomondo A, Di Sciacca R, Di Raimondo D et al. Inflammation as a therapeutic target in acute ischemic stroke treatment. Curr. Top. Med. Chem. 9(14), 1240-1260 (2009).
35. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131(4), 1006-1012 (2007).
36. Tleyjeh IM, Kashour T, Hakim FA et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch. Intern. Med. 169(18), 1658-1667 (2009).
37. Department of Health Immunisation www.immunisation.nhs.uk/publications/ Flu-Uptake-final0809.pdf (Accessed 7 December 2009)
38. CDC. Seasona influenza: 2009-2010 Influenza Prevention & Control Recommendations. Influenza Vaccination Coverage Levels www.cdc.gov/flu/ professionals/acip/ coveragelevels.htm (Accessed 7 December 2009)
39. NICE Technology Appraisal. Amantadine, Oseltamivir and Zanamivir for the Treatment of Influenza. MIMS, TA, 168 (2009) http://guidance.nice.org.uk/TA168/ Guidance/pdf/English (Accessed 12 January 2010)
40. WHO. Global Alert Response (GAR): Antiviral drugs and pandemic (H1N1) (2009) www.who.int/csr/disease/swineflu/ frequently-asked-questions/swineflu- faq- antivirals/en/index.html (Accessed 7 December 2009)